|Mr. Derek J. Maetzold||Founder, CEO, Pres & Director||1.02M||N/A||1962|
|Mr. Frank Stokes||Chief Financial Officer||656.26k||N/A||1970|
|Mr. Bernhard E. Spiess||Chief Bus. Officer||528.35k||N/A||1960|
|Ms. Kristen M. Oelschlager R.N., RN||Chief Operating Officer||N/A||N/A||1968|
|Camilla Zuckero||Exec. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Alice Bahner Izzo||VP of Marketing||N/A||N/A||N/A|
|Mr. Toby W. Juvenal||Chief Commercial Officer||N/A||N/A||1961|
|Dr. Robert W. Cook||Sr. VP of R&D||N/A||N/A||1972|
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 9.